November 4, 2016 Rentschler expands cGMP manufacturing capacity following increased international demand
Laupheim, Germany, November 4, 2016 –Rentschler Biotechnologie GmbH, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced the opening of a new single-use bioreactor at the Company’s site in Laupheim with a capacity of 2,000 liters. Rentschler continues to expand its cGMP manufacturing capacity only a few weeks after putting into operation an innovative Twin system with two 3,000 liter stainless steel bioreactors.
In combination with its first 2,000 liter single-use bioreactor put into operation in 2015, Rentschler now has two 1,000 liter and two 2,000 liter single-use manufacturing systems available. This enables the complete manufacturing of recombinant proteins in single-use bioreactors, also for late stage clinical development and market supply of biopharmaceuticals for the treatment of severe illnesses.
“Only a few weeks after putting into operation our Twin system, Rentschler again is expanding its manufacturing capacity with this new 2,000 liter single-use bioreactor. This capacity expansion will enable us to meet the continuous growth in international business,” Dr. Frank Mathias, Chief Executive Officer of Rentschler Biotechnologie GmbH, commented.
With its full-service concept, Rentschler offers targeted and client-specific solutions that meet highly diverse requirements in terms of scale, manufacturing volumes, and manufacturing characteristics and therefore maximize the efficiency and suitability of biopharmaceutical manufacturing.
“In the future, providing both, single-use and stainless steel technologies, will continue to play an important role and enable greater flexibility – also for our clients. We align our goals with our clients' objectives,” Dr. Frank Mathias added.
In the course of the continuous capacity expansion and investments at the Company’s site in Laupheim, Rentschler is still looking to hire a variety of skilled employees, including process engineers and laboratory technicians in bioprocess development and manufacturing as well as GMP (Good Manufacturing Practices) experts.
Within a few years, single-use systems have led to a paradigm shift in the manufacturing of clinical test materials. Compared to stainless steel bioreactors, single-use systems not only carry a lower contamination risk, but are more cost-effective and can be implemented more quickly. Of particular note is the flexibility offered by single-use systems, as manufacturing processes can be designed modularly and thus easily scaled. In addition, faster product changeover is possible, which enables reduced time-to-market. The two 2,000 liter single-use bioreactors can be run in parallel, thus providing higher throughput while reducing costs.
About Rentschler Biotechnologie GmbH
Rentschler Biotechnologie GmbH, located in Laupheim, Germany, is a leading contract development and manufacturing organization (CDMO) for bioprocess development and biomanufacturing as well as regulatory support. The Company’s clients include innovative biotech companies as well as major pharmaceutical companies around the world, especially in Europe, North America and Asia. Many years of experience, excellence in finding solutions as well as certified quality management and advanced technologies ensure Rentschler’s high quality standard. Rentschler is a privately held company employing 700 people.
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication